Immune Design Corp. (IMDZ) Hit 12-Month High at $5.84

During 2018 Q4 the big money sentiment increased to 1.33. That’s change of 0.15, from 2018Q3’s 1.18. 12 investors sold all, 15 reduced holdings as Immune Design Corp. ratio increased. 24 increased holdings while 12 funds amassed holdings. Funds hold 20.97 million shares thus 5.28% more from 2018Q3’s 19.92 million shares.
Tiaa Cref Invest Ltd Limited Liability Company reported 0% of its capital in Immune Design Corp. (NASDAQ:IMDZ). Jpmorgan Chase And reported 528,964 shs. Blackrock stated it has 2.13M shs or 0% of all its holdings. Meeder Asset Management accumulated 1,818 shs. Deutsche Commercial Bank Ag has 44,049 shs for 0% of their capital. Renaissance Ltd Com owns 524,805 shs for 0% of their capital. Voya Inv Mgmt Ltd Liability Corporation stated it has 13,415 shs or 0% of all its holdings. Moreover, Alliancebernstein Limited Partnership has 0% invested in Immune Design Corp. (NASDAQ:IMDZ) for 14,000 shs. Personal Advsr reported 37,500 shs or 0% of all its holdings. D E Shaw And holds 205,148 shs. 27,122 are held by Boothbay Fund Mngmt Ltd Llc. Legal General Group Inc Plc stated it has 5,795 shs or 0% of all its holdings. Abingworth Limited Liability Partnership owns 352,300 shs. Charles Schwab Inc has invested 0% in Immune Design Corp. (NASDAQ:IMDZ). 44,566 were reported by Acadian Asset Mngmt Limited Liability.

Immune Design Corp. had 5 insider sales and 0 insider purchases since December 4, 2018. This’s net activity of $1.69 million. Another trade for 5,516 shs valued at $8,722 was sold by Brady Stephen R. $5,415 worth of stock was sold by ter Meulen Jan Henrik on Thursday, January 3. Shares for $20,591 were sold by Paya Carlos V. Another trade for 902,000 shs valued at $1.65M was made by BVF PARTNERS L P/IL on Tuesday, December 4.

Today yearly high was hit by Immune Design Corp. (NASDAQ:IMDZ) with $6.19 price target or 6.00 % above today’s $5.84 price per share. Barchart.com announced the yearly high on Mar, 13. It has $282.20M market cap. The company’s valuation will be $16.93 million more at $6.19 price target.

IMDZ is reaching $5.84 during the last trading session, after decreased 0.09%.Currently Immune Design Corp. is uptrending after 97.63% change in last March 13, 2018. IMDZ has also 56,337 shares volume. IMDZ outperformed the S&P500 by 93.26%.

Immune Design Corp. (NASDAQ:IMDZ) Ratings Coverage

In total 2 analysts cover Immune Design (NASDAQ:IMDZ). “Buy” rating has 0, “Sell” are 0, while 2 are “Hold”. (NASDAQ:IMDZ) has 0 bullish analysts. With $7.75 highest and $5.85 lowest target, Immune Design has $5.93 average target or 1.54% above the current ($5.84) price. 5 are the (NASDAQ:IMDZ)’s ratings reports on Mar 13, 2019 according to StockzIntelligence Inc. The stock rating was maintained by H.C. Wainwright with “Buy” on Friday, October 12. On Friday, February 22 the stock of Immune Design Corp. (NASDAQ:IMDZ) earned “Sector Perform” rating by RBC Capital Markets. In Thursday, February 21 report H.C. Wainwright downgraded the stock to “Hold” rating.

For more Immune Design Corp. (NASDAQ:IMDZ) news released briefly go to: Benzinga.com, Benzinga.com, Businesswire.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “65 Biggest Movers From Yesterday – Benzinga” released on February 22, 2019, “The Daily Biotech Pulse: BioMarin (NASDAQ:BMRN) Slips On Earnings, TherapeuticsMD (NASDAQ:TXMD) Posts In-Line Results, Orchard (NASDAQ:ORTX) To Present Immunodeficiency Drug Data – Benzinga” on February 22, 2019, “Merck Begins Tender Offer to Acquire Immune Design – Business Wire” with a publish date: March 05, 2019, “Mid-Morning Market Update: Markets Open Lower; Domino’s Pizza Misses Q4 Views – Benzinga” and the last “Is Immune Design Worth A Second Look? – Seeking Alpha” with publication date: June 12, 2018.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer.The firm is worth $282.20 million. It primarily develops oncology product candidates based on its ZVex and GLAAS product discovery platforms.Currently it has negative earnings. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.